Class information for:
Level 1: MYELODYSPLASTIC SYNDROMES//MYELODYSPLASTIC SYNDROME//AZACITIDINE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
190 3908 37.9 80%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
81 26583 MYELODYSPLASTIC SYNDROMES//ACUTE MYELOID LEUKEMIA//LEUKEMIA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MYELODYSPLASTIC SYNDROMES Author keyword 694 58% 20% 801
2 MYELODYSPLASTIC SYNDROME Author keyword 268 34% 17% 646
3 AZACITIDINE Author keyword 166 68% 4% 147
4 MDS Author keyword 124 34% 8% 302
5 INTERNATIONAL PROGNOSTIC SCORING SYSTEM Author keyword 49 79% 1% 31
6 DEL5Q Author keyword 40 71% 1% 32
7 HYPOMETHYLATING AGENTS Author keyword 40 58% 1% 45
8 CHRONIC MYELOMONOCYTIC LEUKEMIA Author keyword 38 41% 2% 71
9 MYELODYSPLASIA Author keyword 37 23% 4% 140
10 HEMATOL ONCOL CLIN IMMUNOL Address 37 38% 2% 76

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 MYELODYSPLASTIC SYNDROMES 694 58% 20% 801 Search MYELODYSPLASTIC+SYNDROMES Search MYELODYSPLASTIC+SYNDROMES
2 MYELODYSPLASTIC SYNDROME 268 34% 17% 646 Search MYELODYSPLASTIC+SYNDROME Search MYELODYSPLASTIC+SYNDROME
3 AZACITIDINE 166 68% 4% 147 Search AZACITIDINE Search AZACITIDINE
4 MDS 124 34% 8% 302 Search MDS Search MDS
5 INTERNATIONAL PROGNOSTIC SCORING SYSTEM 49 79% 1% 31 Search INTERNATIONAL+PROGNOSTIC+SCORING+SYSTEM Search INTERNATIONAL+PROGNOSTIC+SCORING+SYSTEM
6 DEL5Q 40 71% 1% 32 Search DEL5Q Search DEL5Q
7 HYPOMETHYLATING AGENTS 40 58% 1% 45 Search HYPOMETHYLATING+AGENTS Search HYPOMETHYLATING+AGENTS
8 CHRONIC MYELOMONOCYTIC LEUKEMIA 38 41% 2% 71 Search CHRONIC+MYELOMONOCYTIC+LEUKEMIA Search CHRONIC+MYELOMONOCYTIC+LEUKEMIA
9 MYELODYSPLASIA 37 23% 4% 140 Search MYELODYSPLASIA Search MYELODYSPLASIA
10 DECITABINE 35 32% 2% 89 Search DECITABINE Search DECITABINE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 REFRACTORY ANEMIA 127 53% 4% 170
2 SYNDROMES MDS 107 82% 2% 63
3 FAB CLASSIFICATION 100 75% 2% 72
4 AZACITIDINE 99 54% 3% 129
5 SCORING SYSTEM 92 17% 12% 484
6 PROGNOSTIC SCORING SYSTEM 84 35% 5% 194
7 MDS 80 30% 6% 222
8 WORKING CONFERENCE 73 85% 1% 39
9 CHROMOSOME 5Q DELETION 73 80% 1% 45
10 CHRONIC MYELOMONOCYTIC LEUKEMIA 70 25% 6% 245

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CURRENT HEMATOLOGIC MALIGNANCY REPORTS 3 10% 1% 24

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Comparison Between Decitabine and Azacitidine for the Treatment of Myelodysplastic Syndrome: A Meta-Analysis With 1392 Participants 2015 4 23 83%
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 2013 54 250 68%
The World Health Organization (WHO) classification of the myeloid neoplasms 2002 1098 85 34%
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience 2008 111 26 92%
Current state of prognostication and risk stratification in myelodysplastic syndromes 2015 1 77 96%
Mechanisms of Disease: Myelodysplastic Syndromes. 2009 180 97 72%
The inflammatory microenvironment in MDS 2015 2 79 53%
Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies 2015 1 41 85%
How we treat higher-risk myelodysplastic syndromes 2014 12 91 77%
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS 2014 8 56 91%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HEMATOL ONCOL CLIN IMMUNOL 37 38% 1.9% 76
2 LEUKEMIA PROGRAM 15 33% 0.9% 37
3 HEMATOL ONCOL BLOOD DISORDERS 15 26% 1.3% 49
4 LLR MOL HAEMATOL UNIT 12 75% 0.2% 9
5 RUSH CANC 9 34% 0.5% 21
6 HAEMATOL ONCOL CLIN IMMUNOL 8 37% 0.4% 17
7 MALIGNANT HEMATOL 7 21% 0.8% 30
8 NDCLS 7 38% 0.4% 14
9 TRANSLAT HEMATOL ONCOL 7 22% 0.7% 26
10 HOP AVICENNE 6 10% 1.4% 53

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000175440 JUVENILE MYELOMONOCYTIC LEUKEMIA//JMML//JUVENILE MYELOMONOCYTIC LEUKAEMIA
2 0.0000136015 TETRASOMY 8//NEAR TETRAPLOIDY//TRISOMY 4
3 0.0000096229 ZEBULARINE//DECITABINE//FAZARABINE
4 0.0000084804 ACUTE ERYTHROLEUKEMIA//PURE ERYTHROID LEUKEMIA//ACUTE ERYTHROID LEUKEMIA
5 0.0000079919 CHRONIC NEUTROPHILIC LEUKEMIA//CHRONIC NEUTROPHILIC LEUKAEMIA//COLONY STIMULATING FACTOR 3 RECEPTOR MUTATION
6 0.0000076317 TUMOR CLONALITY//CLONAL REMISSION//M27 BETA
7 0.0000075920 PARANEOPLASTIC VASCULITIS//PALMAR FASCIITIS//LEUKEMIC ARTHRITIS
8 0.0000066912 NUP98//T711P15P15//DDX10
9 0.0000066728 CHROMOSOME 5 ABNORMALITY//PHARM NTHC NARILIS//UNIDAD HEMATOL CLIN
10 0.0000063431 EVI1//EVI 1//3Q21Q26 SYNDROME